Staining for p53 and Ki-67 increases the sensitivity of EUS-FNA to detect pancreatic malignancy

Table 1 Patient data for those with pancreatic lesions definitively diagnosed as benign or malignant (not all laboratory data were available for each patient)

	Malignant (n = 49)	Benign (n = 12)
Age [median (range)]	61 (34-88)	60 (15-73)
Sex (M:F)	27:22:00	8:04
Location of pancreatic lesion
Head/uncinate process	39	10
Body	9	2
Tail	1	0
Serum enzymes [median (range)]
Total bilirubina (mg/dL)	3 (1-28)	1 (0-5)
AST (U/L)	63 (11-603)	35 (13-182)
ALT (U/L)	74 (5-694)	33 (13-167)
ALP (U/L)	211 (54-1307)	136 (59-1409)
Amylase (U/L)	94 (15-182)	80 (11-285)
Lipase (U/L)	26 (13-199)	29 (16-95)
Serum tumor markers [median (range)]
CEA (ng/mL)	5 (1-403)	3 (0-32)
CA19-9a (U/mL)	339 (0-9929)	28 (0-1507)

^aP < 0.05, benign group compared with malignant. ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CEA: carcinoembryonic antigen.